相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma
Margret Merino et al.
PEDIATRIC BLOOD & CANCER (2022)
FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells
Qiong Cheng et al.
CELLS (2021)
Rapamycin and trametinib: a rational combination for treatment of NSCLC
Chao-Yue Sun et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Catherine B. Meador et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
Georg Hess et al.
HEMASPHERE (2020)
Polytherapy and Targeted Cancer Drug Resistance
Nilanjana Chatterjee et al.
TRENDS IN CANCER (2019)
Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome
Lizhou Jia et al.
MEDICAL SCIENCE MONITOR (2018)
The Role of PI3K in Met Driven Cancer: A Recap
Alexia Hervieu et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
MET Tyrosine Kinase Receptor Expression and Amplification as Prognostic Biomarkers of Survival in Gastroesophageal Adenocarcinoma
Daniel V. T. Catenacci et al.
CANCER (2017)
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
Julie M. Vose
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
Lucia Raimondo et al.
ONCOTARGET (2016)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli et al.
ONCOTARGET (2016)
C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome
Ya-Ping Xu et al.
JOURNAL OF CANCER (2016)
Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer
Demin Jiao et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma
Konstantin Golovine et al.
CANCER BIOLOGY & THERAPY (2015)
Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape
Ammad Ahmad Farooqi et al.
CELL BIOCHEMISTRY AND FUNCTION (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Drug resistance to targeted therapies: Deja vu all over again
Floris H. Groenendijk et al.
MOLECULAR ONCOLOGY (2014)
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Rajani Kanteti et al.
PLOS ONE (2014)
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Christiane R. Maroun et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Radiosensitization of brain metastasis by targeting c-MET
Heekyoung Yang et al.
LABORATORY INVESTIGATION (2013)
The paradox of Akt-mTOR interactions
Lakshmipathi Vadlakonda et al.
FRONTIERS IN ONCOLOGY (2013)
Targeting mTOR in mantle cell lymphoma: Current and future directions
Sonali M. Smith
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2012)
Mechanisms of FGFR-mediated carcinogenesis
Imran Ahmad et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
G. Minuti et al.
BRITISH JOURNAL OF CANCER (2012)
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas
Feng Wei et al.
CANCER LETTERS (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
分享论文
